Aug 2, 2022
|
Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
|
Jul 28, 2022
|
Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
|
Jul 1, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Jun 30, 2022
|
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
|
Jun 21, 2022
|
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
|
Jun 3, 2022
|
Ardelyx to Present at the Jefferies 2022 Healthcare Conference
|
May 24, 2022
|
Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
|
May 17, 2022
|
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
|
May 16, 2022
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
May 5, 2022
|
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
|